Summit Therapeutics is trading 4.2% lower at $16.40, with no clear company-specific catalyst for the September 23, 2026 decline. - Reports of potential AstraZeneca licensing discussions described shares rising sharply, making that news inconsistent with the current decline. - Broader equities are weaker, while biotechnology is outperforming; neither provides a strong explanation. - Profit-taking or trading-specific pressure may be contributing, but that remains unconfirmed.